Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1993 1
1994 2
1995 6
1996 14
1997 32
1998 74
1999 94
2000 134
2001 189
2002 240
2003 349
2004 389
2005 520
2006 542
2007 526
2008 594
2009 539
2010 591
2011 659
2012 658
2013 625
2014 674
2015 633
2016 610
2017 626
2018 630
2019 633
2020 594
2021 609
2022 42
Text availability
Article attribute
Article type
Publication date

Search Results

10,554 results
Results by year
Filters applied: . Clear all
Page 1
Effects of atorvastatin on chronic subdural hematoma: A systematic review.
Qiu S, Zhuo W, Sun C, Su Z, Yan A, Shen L. Qiu S, et al. Medicine (Baltimore). 2017 Jun;96(26):e7290. doi: 10.1097/MD.0000000000007290. Medicine (Baltimore). 2017. PMID: 28658127 Free PMC article. Review.
BACKGROUND: The high recurrent rate of chronic subdural hematoma (CSDH) has consistently confused the neurosurgeons, and the role of atorvastatin in the management of CSDH has remained unclear over past decade, and atorvastatin seems to be a safe and cost-effective …
BACKGROUND: The high recurrent rate of chronic subdural hematoma (CSDH) has consistently confused the neurosurgeons, and the role of ator
Atorvastatin: A Review of Analytical Methods for Pharmaceutical Quality Control and Monitoring.
Kogawa AC, Pires AEDT, Salgado HRN. Kogawa AC, et al. J AOAC Int. 2019 May 1;102(3):801-809. doi: 10.5740/jaoacint.18-0200. Epub 2018 Dec 18. J AOAC Int. 2019. PMID: 30563586 Review.
Background: Atorvastatin, a lipid-regulating drug, was the best-selling drug in the world in the early 2000s. ...Therefore, the suitability of existing methods for the determination of atorvastatin can be made to adhere to the current analytical chemistry. ...
Background: Atorvastatin, a lipid-regulating drug, was the best-selling drug in the world in the early 2000s. ...Therefore, the suita …
Hepatotoxicity of statins and other lipid-lowering agents.
Björnsson ES. Björnsson ES. Liver Int. 2017 Feb;37(2):173-178. doi: 10.1111/liv.13308. Epub 2016 Nov 27. Liver Int. 2017. PMID: 27860156 Review.
This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs. Both atorvastatin and simvastatin have been associated with more than 50 case reports of liver injury and other statins have been implicated …
This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs. Both …
Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice.
Taniguti EH, Ferreira YS, Stupp IJV, Fraga-Junior EB, Doneda DL, Lopes L, Rios-Santos F, Lima E, Buss ZS, Viola GG, Vandresen-Filho S. Taniguti EH, et al. Brain Res Bull. 2019 Mar;146:279-286. doi: 10.1016/j.brainresbull.2019.01.018. Epub 2019 Jan 25. Brain Res Bull. 2019. PMID: 30690060
In the present study, we aimed to investigate the effect of atorvastatin treatment on lipopolysaccharide (LPS) induced depressive-like behaviour in mice. Mice were treated with atorvastatin (1 or 10 mg/kg, v.o.) or fluoxetine (30 mg/kg, positive control, v.o.) for 7 …
In the present study, we aimed to investigate the effect of atorvastatin treatment on lipopolysaccharide (LPS) induced depressive-lik …
Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.
Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, Mao Y, Yuan X, Fei Z, Zhao Y, Yu X, Poon WS, Zhu X, Liu N, Kang D, Sun T, Jiao B, Liu X, Yu R, Zhang J, Gao G, Hao J, Su N, Yin G, Zhu X, Lu Y, Wei J, Hu J, Hu R, Li J, Wang D, Wei H, Tian Y, Lei P, Dong JF, Zhang J. Jiang R, et al. JAMA Neurol. 2018 Nov 1;75(11):1338-1346. doi: 10.1001/jamaneurol.2018.2030. JAMA Neurol. 2018. PMID: 30073290 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomly assigned to receive either 20 mg of atorvastatin or placebo daily for 8 weeks and were followed up for an additional 16 weeks. ...The baseline HV and clinical presentations were similar between patients who were taking atorvastatin
INTERVENTIONS: Patients were randomly assigned to receive either 20 mg of atorvastatin or placebo daily for 8 weeks and were followed …
Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
Berwanger O, Santucci EV, de Barros E Silva PGM, Jesuíno IA, Damiani LP, Barbosa LM, Santos RHN, Laranjeira LN, Egydio FM, Borges de Oliveira JA, Dall Orto FTC, Beraldo de Andrade P, Bienert IRC, Bosso CE, Mangione JA, Polanczyk CA, Sousa AGMR, Kalil RAK, Santos LM, Sposito AC, Rech RL, Sousa ACS, Baldissera F, Nascimento BR, Giraldez RRCV, Cavalcanti AB, Pereira SB, Mattos LA, Armaganijan LV, Guimarães HP, Sousa JEMR, Alexander JH, Granger CB, Lopes RD; SECURE-PCI Investigators. Berwanger O, et al. JAMA. 2018 Apr 3;319(13):1331-1340. doi: 10.1001/jama.2018.2444. JAMA. 2018. PMID: 29525821 Free PMC article. Clinical Trial.
All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication. ...No cases of hepatic failure were reported; 3 cases of rhabdomyolysis were reported in the placebo group (0.1%) and 0 in the atorvastatin group. CO …
All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication. ...No cases of h …
Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis.
Liping Z, Xiufang L, Tao Y, Baomin Z, Houshuai T. Liping Z, et al. Pak J Pharm Sci. 2018 Sep;31(5(Special)):2203-2208. Pak J Pharm Sci. 2018. PMID: 30463813
The results showed that 10 mg rosuvastatin was more effective than 20 mg atorvastatin in lowering serum lipid level and elevating ABI index, ABI as rosuvastatin group (0.7820.236) and atorvastatin group(0.5410.196). ...The TC/mmolL-1 is 2.830.56 in rosuvastatin grou …
The results showed that 10 mg rosuvastatin was more effective than 20 mg atorvastatin in lowering serum lipid level and elevating ABI …
Response.
Bedi P, Hill A. Bedi P, et al. Chest. 2018 Feb;153(2):580-581. doi: 10.1016/j.chest.2017.11.028. Chest. 2018. PMID: 29406231 No abstract available.
Atorvastatin-Associated Gynecomastia.
Famularo G, Sarrecchia C. Famularo G, et al. Ann Pharmacother. 2021 Oct;55(10):1300-1301. doi: 10.1177/1060028021988994. Epub 2021 Jan 20. Ann Pharmacother. 2021. PMID: 33472378 No abstract available.
Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
Stein B, Ward T, Hale G, Lyver E. Stein B, et al. Ann Pharmacother. 2020 May;54(5):405-413. doi: 10.1177/1060028019888487. Epub 2019 Nov 12. Ann Pharmacother. 2020. PMID: 31718234
Current evidence demonstrates efficacy of high-intensity statin therapy in reducing major adverse cardiovascular events; yet the comparative safety profile between high-intensity statin agents remains unknown. In 2011, when atorvastatin became generic, the Veteran's
Current evidence demonstrates efficacy of high-intensity statin therapy in reducing major adverse cardiovascular events; yet the comparative …
10,554 results
You have reached the last available page of results. Please see the User Guide for more information.